MA53721A - Modulateurs de la monoacylglycérol lipase - Google Patents

Modulateurs de la monoacylglycérol lipase

Info

Publication number
MA53721A
MA53721A MA053721A MA53721A MA53721A MA 53721 A MA53721 A MA 53721A MA 053721 A MA053721 A MA 053721A MA 53721 A MA53721 A MA 53721A MA 53721 A MA53721 A MA 53721A
Authority
MA
Morocco
Prior art keywords
monoacylglycerol lipase
modulators
lipase modulators
monoacylglycerol
lipase
Prior art date
Application number
MA053721A
Other languages
English (en)
French (fr)
Inventor
Michael K Ameriks
Gang Chen
Chaofeng Huang
Brian Ngo Laforteza
Suchitra Ravula
Emma Helen Southgate
Wei Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA53721A publication Critical patent/MA53721A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
MA053721A 2018-09-28 2019-09-27 Modulateurs de la monoacylglycérol lipase MA53721A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862738600P 2018-09-28 2018-09-28

Publications (1)

Publication Number Publication Date
MA53721A true MA53721A (fr) 2021-09-15

Family

ID=68109428

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053721A MA53721A (fr) 2018-09-28 2019-09-27 Modulateurs de la monoacylglycérol lipase

Country Status (26)

Country Link
US (3) US20200102303A1 (https=)
EP (1) EP3856178B1 (https=)
JP (2) JP7482116B2 (https=)
KR (1) KR102911066B1 (https=)
CN (1) CN113164459B (https=)
AU (2) AU2019350624B2 (https=)
BR (1) BR112021005896A2 (https=)
CA (1) CA3111380A1 (https=)
CL (1) CL2021000757A1 (https=)
CO (1) CO2021003944A2 (https=)
CR (1) CR20210153A (https=)
DO (1) DOP2021000051A (https=)
EA (1) EA202190886A1 (https=)
EC (1) ECSP21021381A (https=)
IL (1) IL281812A (https=)
JO (1) JOP20210058A1 (https=)
MA (1) MA53721A (https=)
MX (1) MX2021003737A (https=)
MY (1) MY205440A (https=)
NI (1) NI202100023A (https=)
PE (1) PE20211773A1 (https=)
PH (1) PH12021550659A1 (https=)
SA (2) SA522441561B1 (https=)
SG (1) SG11202102281VA (https=)
TW (1) TWI863931B (https=)
WO (1) WO2020065613A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
EP3856178B1 (en) 2018-09-28 2026-03-11 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
WO2020065614A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US20220315602A1 (en) * 2019-06-04 2022-10-06 Hager Biosciences, Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
MX2022003819A (es) * 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv Ligandos de pet de mgl radiomarcados.
BR112022019077A2 (pt) * 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
WO2022150962A1 (en) * 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
US20240270743A1 (en) * 2021-08-11 2024-08-15 Landos Biopharma, Inc. Tetrahydropyrazolopyridine-analog ligands of nlrx1 and uses thereof
AR127955A1 (es) 2021-12-16 2024-03-13 Hoffmann La Roche Nuevos compuestos heterocíclicos
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
CN115872995B (zh) * 2022-12-27 2024-10-01 上海凌凯科技股份有限公司 一种吡唑并吡啶化合物及一种羧酸衍生物的制备方法
CN116606298A (zh) * 2023-05-26 2023-08-18 康化（上海）新药研发有限公司 2,3-二氢-[1,4]二噁烷并[2,3-b]吡啶-8-羧酸的合成方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
JP2005537290A (ja) 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
CA2493625A1 (en) 2002-07-25 2004-02-19 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
FR2857363B1 (fr) 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
ATE546452T1 (de) 2003-09-23 2012-03-15 Vertex Pharma Pyrazolopyrrolderivate als proteinkinaseinhibitoren
AU2005277283A1 (en) 2004-08-23 2006-03-02 Merck Sharp & Dohme Corp. Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20080146612A1 (en) 2005-01-27 2008-06-19 Astrazeneca Ab Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
JP2009531390A (ja) 2006-03-31 2009-09-03 ノバルティス アクチエンゲゼルシャフト 有機化合物
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
FR2915197B1 (fr) 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
US8349858B2 (en) 2007-06-21 2013-01-08 Merck Sharp & Dohme Polycyclic guanine derivatives and use thereof
WO2009023623A1 (en) 2007-08-10 2009-02-19 H, Lundbeck A/S Heteroaryl amide analogues
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
CA2722035C (en) 2008-04-22 2016-10-11 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted p2x7 antagonists
EP2370437B1 (en) 2008-11-25 2013-09-04 Nerviano Medical Sciences S.r.l. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
WO2010124122A1 (en) 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
US8455476B2 (en) 2009-04-22 2013-06-04 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
ES2590987T3 (es) 2009-04-29 2016-11-24 Glaxo Group Limited Derivados de 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]pirazina como moduladores de P2X7
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
EP2552920B1 (en) 2010-04-02 2017-03-15 Ogeda Sa Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
EP2558661A4 (en) 2010-04-16 2014-10-29 Fernandez Rodrigo Graf FOLDABLE STRUCTURES FOR CONSTRUCTION
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
US20130196986A1 (en) 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
JP2013537920A (ja) * 2010-09-27 2013-10-07 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ阻害剤としてのオキソピペラジン−アゼチジンアミド及びオキソジアゼピン−アゼチジンアミド
WO2012054716A1 (en) 2010-10-22 2012-04-26 Janssen Pharmaceutica Nv. Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
JP2013540160A (ja) * 2010-10-22 2013-10-31 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ阻害剤としてのアミノ−ピロリジン−アゼチジンジアミド
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
WO2013050424A1 (en) 2011-10-03 2013-04-11 Euroscreen S.A. NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF
EP2766345B1 (en) * 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9273947B2 (en) 2012-02-07 2016-03-01 Lg Innotek Co., Ltd. Sensing magnet apparatus for motor
JP5205547B1 (ja) 2012-04-20 2013-06-05 株式会社ノイズ研究所 放射信号可視化装置
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
MX2015004721A (es) 2012-10-15 2016-01-25 Epizyme Inc Compuestos de benceno sustituidos.
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
WO2014100818A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
EP2935248B1 (en) 2012-12-21 2018-02-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
AU2014214846A1 (en) 2013-02-08 2015-07-23 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
PT2964229T (pt) 2013-03-06 2020-03-23 Janssen Pharmaceutica Nv Moduladores de piridina benzimidazol-2-ilo do recetor h4 de histamina
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
SG11201507255QA (en) 2013-03-14 2015-10-29 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
PE20151727A1 (es) 2013-03-14 2015-12-17 Boehringer Ingelheim Int Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
NZ710765A (en) 2013-03-14 2020-05-29 Glaxosmithkline Ip No 2 Ltd 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
CN105209449B (zh) 2013-03-14 2019-02-01 库拉德夫制药私人有限公司 犬尿氨酸途径的抑制剂
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
ES2654288T3 (es) 2013-03-14 2018-02-13 Janssen Pharmaceutica, N.V. Moduladores de P2X7
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
JP6275242B2 (ja) 2013-03-29 2018-02-07 オゲダ エス．エー． 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−（８−メチル）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法
US20150057260A1 (en) 2013-08-22 2015-02-26 Genentech, Inc. Alkynyl alcohols and methods of use
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
AU2015314851B2 (en) 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
CA2960968A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
WO2016039983A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulating n-acyl-triazolopyrazines
RU2742305C2 (ru) 2014-12-30 2021-02-04 Новира Терапьютикс, Инк. Производные и способы лечения инфекций гепатита в
US10106556B2 (en) 2015-03-30 2018-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
US10934276B2 (en) 2016-12-16 2021-03-02 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
CN110198944A (zh) 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
WO2020065614A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
EP3856178B1 (en) 2018-09-28 2026-03-11 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
WO2020211798A1 (zh) 2019-04-16 2020-10-22 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
MX2022003819A (es) 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv Ligandos de pet de mgl radiomarcados.
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase

Also Published As

Publication number Publication date
AU2019350624A1 (en) 2021-03-18
MX2021003737A (es) 2021-05-14
EA202190886A1 (ru) 2021-09-07
PH12021550659A1 (en) 2022-02-21
TWI863931B (zh) 2024-12-01
EP3856178B1 (en) 2026-03-11
US20200102303A1 (en) 2020-04-02
DOP2021000051A (es) 2022-05-31
BR112021005896A2 (pt) 2021-07-27
SA521421575B1 (ar) 2024-08-11
PE20211773A1 (es) 2021-09-08
MY205440A (en) 2024-10-21
US12577243B2 (en) 2026-03-17
US20220332713A1 (en) 2022-10-20
JP2024096702A (ja) 2024-07-17
AU2025226693A1 (en) 2025-09-25
CA3111380A1 (en) 2020-04-02
CL2021000757A1 (es) 2021-08-27
JP7482116B2 (ja) 2024-05-13
JP2022502424A (ja) 2022-01-11
NI202100023A (es) 2021-09-07
SG11202102281VA (en) 2021-04-29
EP3856178A1 (en) 2021-08-04
CN113164459A (zh) 2021-07-23
JOP20210058A1 (ar) 2021-03-24
KR20210069080A (ko) 2021-06-10
AU2019350624B2 (en) 2025-07-24
KR102911066B1 (ko) 2026-01-09
ECSP21021381A (es) 2021-04-29
IL281812A (en) 2021-05-31
SA522441561B1 (ar) 2024-08-11
CN113164459B (zh) 2024-09-03
US20230145249A1 (en) 2023-05-11
TW202028198A (zh) 2020-08-01
WO2020065613A1 (en) 2020-04-02
US11820766B2 (en) 2023-11-21
CO2021003944A2 (es) 2021-04-19
CR20210153A (es) 2021-05-11

Similar Documents

Publication Publication Date Title
MA53721A (fr) Modulateurs de la monoacylglycérol lipase
DK3743406T3 (da) Tmem16a modulatorer
EP3861130A4 (en) GENETIC MODULATORS
MA53722A (fr) Modulateurs de la monoacylglycérol lipase
IL283967A (en) Modulators of hsd17b13 expression
IL281492A (en) Modulators of pnpla3 expression
HUE062866T2 (hu) TREX-1 modulátorok
EP4103557C0 (en) MONOACYLGLYCEROL LIPASE MODULATORS
EP3675849A4 (en) TETRAHYDROCANNABINOL MODULATORS
EP3601569A4 (en) PCSK9 EXPRESSION MODULATORS
DK3749669T6 (da) Ahr-modulatorer
MA53924A (fr) Modulateurs de l'expression d'apol1
HUE058145T2 (hu) Deformálható érzékelõ
EP3914256A4 (en) GPR35 MODULATORS
EP3821026A4 (en) MANIPULATED ENZYME VARIANTS OF PHOSPHOPENTOMUTASE
EP4192957A4 (en) Trpml modulators
EP3758704A4 (en) IRF4 EXPRESSION MODULATORS
EP4025957C0 (en) ELECTRO-OPTIC MODULATOR
EP4035739A4 (en) HYDROGEL
EP3777974C0 (de) Lichtapplikator
EP3958804A4 (en) LENS APPLICATOR
EP3779540A4 (en) Optical modulator
EP3954003A4 (en) CONTACT SPLICE
EP4022049A4 (en) MANIPULATED LIGASE VARIANTS
EP3994774C0 (en) OPTICAL SYSTEM